3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Ovarian Neoplasms
4
Endometrial Neoplasms
4
Salivary Gland Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Breast Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Fallopian Tube Neoplasms
1
Interventions
pembrolizumab
5
Magnetic Resonance Spectroscopy
4
Trastuzumab
3
Nivolumab
3
ulixertinib
2
palbociclib
2
lenvatinib
2
belinostat
2
Sunitinib
2
Specimen Handling
2
Fluorodeoxyglucose F18
2
FAPI-46
2
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
tislelizumab
1
tipifarnib
1
spartalizumab
1
sargramostim
1
sapanisertib
1
relatlimab
1
pertuzumab
1
pazopanib
1
osimertinib
1
omipalisib
1
olaparib
1
methyl N-acetylsibirosaminide
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
trastuzumab deruxtecan
×
Gynecologic
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled